Herein, we report successful nIFN-β plus RBV therapy in a chronic hepatitis C patient after discontinuation of IFN-α plus RBV therapy, pegIFN-α therapy, and natural IFN-α therapy following arrhythmia, IP, and severe neurovegetative symptoms, respectively. This evidence concerns the gene IFNA2 and cardiac arrhythmia.